Sirnaomics Revenue and Competitors
Estimated Revenue & Valuation
- Sirnaomics's estimated annual revenue is currently $7.5M per year.
- Sirnaomics's estimated revenue per employee is $100,500
- Sirnaomics's total funding is $267M.
Employee Data
- Sirnaomics has 75 Employees.
- Sirnaomics grew their employee count by -16% last year.
Sirnaomics's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Development Officer | Reveal Email/Phone |
2 | Chief Production Officer | Reveal Email/Phone |
3 | VP Regulatory Affairs | Reveal Email/Phone |
4 | VP Human Resources | Reveal Email/Phone |
5 | Senior Director Technical Operations/Engineering | Reveal Email/Phone |
6 | Chief Medical Officer | Reveal Email/Phone |
7 | Senior Director Toxicology | Reveal Email/Phone |
8 | Executive Director, Chief Scientific Officer | Reveal Email/Phone |
9 | Chief Operation Officer | Reveal Email/Phone |
10 | Senior Director, Bioinformatics, China CIO | Reveal Email/Phone |
Sirnaomics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7M | 35 | -3% | N/A | N/A |
#2 | $7.2M | 36 | -5% | N/A | N/A |
#3 | $10.5M | 52 | -9% | N/A | N/A |
#4 | $344.1M | 1712 | 9% | N/A | N/A |
#5 | $27.5M | 137 | 6% | N/A | N/A |
#6 | $107.3M | 534 | 9% | N/A | N/A |
#7 | $12.9M | 64 | 28% | N/A | N/A |
#8 | $31.6M | 157 | 1% | N/A | N/A |
#9 | $31.4M | 156 | 7% | N/A | N/A |
#10 | $11.5M | 57 | 30% | N/A | N/A |
What Is Sirnaomics?
Sirnaomics is a clinical stage biopharmaceutical company leveraging an outstanding level of knowledge and experience in RNA interference (RNAi) technology to forge a path to high value creation through discovery and development of therapeutics for human disorders with unmet medical needs. The key differentiating feature is the proprietary Polypeptide Nano-Particle (PNP) technology for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver. The clinical development pipeline is focused on oncology and fibrosis indications. Through the internal research and collaborations with prominent labs at NIH, Johns Hopkins, Duke, University of Maryland and Penn State, Sirnaomics has developed a strong portfolio of intellectual property covering RNAi therapeutic products, key biological mechanisms of action and unique PNP delivery system. The management team collectively has extensive drug development experience, as well as specialized expertise in the areas of oligonucleotide therapeutics and nanoparticle-mediated delivery.
keywords:Biotechnology$267M
Total Funding
75
Number of Employees
$7.5M
Revenue (est)
-16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sirnaomics News
Respiratory Rate Sensors Market Business Opportunities, Survey, Analysis And Industry Outlook | Merck & Co., Inc., Sirnaomics, NIHON KOHDEN...
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the...
Sirnaomics has dosed the first healthy subject in a Phase I clinical trial analysing the potential of STP707 to treat liver fibrosis in...
GAITHERSBURG, Md. and SUZHOU BIOBAY, China, July 14, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced dose administration for the first patient in a Phase 2 stu ...
GAITHERSBURG, Md. and SUZHOU BIOBAY, China, July 1, 2021 /PRNewswire/ -- Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed $105 million in a Series E financing. This round of funding was led by Rotating Bo ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $19.1M | 76 | 29% | N/A |
#2 | $11.8M | 76 | -14% | $158.7M |
#3 | $11.6M | 80 | 21% | N/A |
#4 | $16.8M | 80 | 48% | N/A |
#5 | $18M | 82 | 34% | N/A |